Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Qujing Hengsheng Closes $14 Million Pre-A Round for Minimally Invasive Imaging

publication date: May 11, 2020

Qujing Hengsheng Science and Technology of Beijing, a medical device maker, closed a $14 million Pre-A funding to develop novel cardiovascular and intracavitary imaging technologies. The company's S1 intravascular imaging system combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT). Qujing Hengsheng claims each of the two technologies already surpass the performance of foreign-made technologies, while combining the two via a single catheter allows doctors to choose the best modality, reducing risk in percutaneous coronary intervention (PCI) procedures. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital